Rottapharm Biotech is an R&D company dedicated to innovative drug discovery. Born as a research-and-technology-driven company, Rottapharm Biotech is the spin-off of the former R&D division of Rottapharm|Madaus, of which it retained the whole capabilities, infrastructures, and innovative drug discovery programs and assets.
Rottapharm Biotech operates with a mixed model involving innovative new chemical entities (NCEs; small molecules) and cutting-edge biotherapeutics including monoclonal antibodies.
Thanks to more than 50 years of experience in the management of both an R&D pipeline and a portfolio of marketed products, our scientists have gained a large expertise in different therapeutic areas, especially rheumatology (with a special focus on osteoarthritis and rheumatoid arthritis) and gastroenterology, but also gynaecology, bronchopneumology, cardiovascular and metabolism disorders, and Central Nervous System. Such expertise in drug discovery and development includes: new target validation; development of animal models; pharmacological and pharmacokinetic characterization of new drug candidates; original formulation; and, finally, design of innovative clinical trials in the areas of expertise.
Our business model consists of a flexible approach where drug development is carried out mainly on internal proprietary discoveries, but also on external projects deriving from early-stage in-licensing or other forms of collaboration. Opportunities for out-licensing are considered during any development phase, but are pursued systematically after the clinical proof of concept has been achieved.